(Q43478583)

23 November 2017

title

Persistence and adherence to proton pump inhibitors in daily clinical practice (English)

1 reference

23 November 2017

2

Siersema PD

1 reference

23 November 2017

Van Soest EM

1

1 reference

23 November 2017

Dieleman JP

series ordinal

3

1 reference

23 November 2017

Sturkenboom MC

series ordinal

4

1 reference

23 November 2017

Kuipers EJ

series ordinal

5

1 reference

23 November 2017

language of work or name

English

0 references

publication date

1 July 2006

1 reference

Alimentary Pharmacology & Therapeutics

23 November 2017

published in

1 reference

23 November 2017

volume

24

1 reference

23 November 2017

issue

2

1 reference

23 November 2017

page(s)

377-385

1 reference

Review article: the long-term use of proton-pump inhibitors

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

A chronic disease score from automated pharmacy data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.02982.X

10.1111/J.1365-2036.2006.02982.X

21 January 2018

Identifiers

DOI

1 reference

23 November 2017

1 reference